Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
A new community-led network called PRADA enables underrepresented patients living with MS to help set research priorities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results